251 related articles for article (PubMed ID: 27083881)
1. Update on the pharmacotherapy of cerebellar and central vestibular disorders.
Kalla R; Teufel J; Feil K; Muth C; Strupp M
J Neurol; 2016 Apr; 263 Suppl 1():S24-9. PubMed ID: 27083881
[TBL] [Abstract][Full Text] [Related]
2. Aminopyridines and Acetyl-DL-leucine: New Therapies in Cerebellar Disorders.
Kalla R; Strupp M
Curr Neuropharmacol; 2019; 17(1):7-13. PubMed ID: 30182858
[TBL] [Abstract][Full Text] [Related]
3. Aminopyridines for the treatment of cerebellar and ocular motor disorders.
Strupp M; Kalla R; Glasauer S; Wagner J; Hüfner K; Jahn K; Brandt T
Prog Brain Res; 2008; 171():535-41. PubMed ID: 18718350
[TBL] [Abstract][Full Text] [Related]
4. Update on the Pharmacotherapy of Cerebellar Ataxia and Nystagmus.
Feil K; Bremova T; Muth C; Schniepp R; Teufel J; Strupp M
Cerebellum; 2016 Feb; 15(1):38-42. PubMed ID: 26519380
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacotherapy of Vestibular Disorders, Nystagmus and Cerebellar Disorders].
Feil K; Böttcher N; Kremmyda O; Muth C; Teufel J; Zwergal A; Brandt T; Strupp M
Fortschr Neurol Psychiatr; 2015 Sep; 83(9):490-8. PubMed ID: 26421856
[TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapy of vestibular and cerebellar disorders and downbeat nystagmus: translational and back-translational research.
Strupp M; Zwergal A; Feil K; Bremova T; Brandt T
Ann N Y Acad Sci; 2015 Apr; 1343():27-36. PubMed ID: 25903394
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacotherapy of Vestibular Disorders, Nystagmus and Cerebellar Disorders].
Feil K; Böttcher N; Kremmyda O; Muth C; Teufel J; Zwergal A; Brandt T; Strupp M
Laryngorhinootologie; 2018 Jan; 97(1):14-23. PubMed ID: 29301160
[TBL] [Abstract][Full Text] [Related]
8. Pharmacotherapy of vestibular disorders and nystagmus.
Strupp M; Kremmyda O; Brandt T
Semin Neurol; 2013 Jul; 33(3):286-96. PubMed ID: 24057832
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological advances in the treatment of neuro-otological and eye movement disorders.
Strupp M; Brandt T
Curr Opin Neurol; 2006 Feb; 19(1):33-40. PubMed ID: 16415675
[TBL] [Abstract][Full Text] [Related]
10. 4-aminopyridine restores vertical and horizontal neural integrator function in downbeat nystagmus.
Kalla R; Glasauer S; Büttner U; Brandt T; Strupp M
Brain; 2007 Sep; 130(Pt 9):2441-51. PubMed ID: 17664175
[TBL] [Abstract][Full Text] [Related]
11. Effects of 4-aminopyridine on nystagmus and vestibulo-ocular reflex in ataxia-telangiectasia.
Shaikh AG; Marti S; Tarnutzer AA; Palla A; Crawford TO; Zee DS; Straumann D
J Neurol; 2013 Nov; 260(11):2728-35. PubMed ID: 23884713
[TBL] [Abstract][Full Text] [Related]
12. The role of regularity and synchrony of cerebellar Purkinje cells for pathological nystagmus.
Glasauer S; Rössert C; Strupp M
Ann N Y Acad Sci; 2011 Sep; 1233():162-7. PubMed ID: 21950989
[TBL] [Abstract][Full Text] [Related]
13. Treatment of downbeat nystagmus with 3,4-diaminopyridine: a placebo-controlled study.
Strupp M; Schüler O; Krafczyk S; Jahn K; Schautzer F; Büttner U; Brandt T
Neurology; 2003 Jul; 61(2):165-70. PubMed ID: 12874393
[TBL] [Abstract][Full Text] [Related]
14. Pharmacotherapy of vestibular and ocular motor disorders, including nystagmus.
Strupp M; Thurtell MJ; Shaikh AG; Brandt T; Zee DS; Leigh RJ
J Neurol; 2011 Jul; 258(7):1207-22. PubMed ID: 21461686
[TBL] [Abstract][Full Text] [Related]
15. Beneficial effects of 3,4-diaminopyridine on positioning downbeat nystagmus in a circumscribed uvulo-nodular lesion.
Helmchen C; Gottschalk S; Sander T; Trillenberg P; Rambold H; Sprenger A
J Neurol; 2007 Aug; 254(8):1126-8. PubMed ID: 17410325
[No Abstract] [Full Text] [Related]
16. Comparison of 10-mg doses of 4-aminopyridine and 3,4-diaminopyridine for the treatment of downbeat nystagmus.
Kalla R; Spiegel R; Claassen J; Bardins S; Hahn A; Schneider E; Rettinger N; Glasauer S; Brandt T; Strupp M
J Neuroophthalmol; 2011 Dec; 31(4):320-5. PubMed ID: 21734596
[TBL] [Abstract][Full Text] [Related]
17. Pharmacotherapy of cerebellar and vestibular disorders.
Lemos J; Manto M
Curr Opin Neurol; 2022 Feb; 35(1):118-125. PubMed ID: 34845147
[TBL] [Abstract][Full Text] [Related]
18. Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine.
Strupp M; Kalla R; Dichgans M; Freilinger T; Glasauer S; Brandt T
Neurology; 2004 May; 62(9):1623-5. PubMed ID: 15136697
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacotherapy of central oculomotor disorders].
Kalla R; Spiegel R; Wagner J; Rettinger N; Jahn K; Strupp M
Nervenarzt; 2008 Dec; 79(12):1377-8, 1380-2, 1384-5. PubMed ID: 18633586
[TBL] [Abstract][Full Text] [Related]
20. 4-Aminopyridine suppresses positional nystagmus caused by cerebellar vermis lesion.
Kremmyda O; Zwergal A; la Fougère C; Brandt T; Jahn K; Strupp M
J Neurol; 2013 Jan; 260(1):321-3. PubMed ID: 23180177
[No Abstract] [Full Text] [Related]
[Next] [New Search]
